Cargando…

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

BACKGROUND: Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activation by low-dose efavirenz in a transgenic mouse model of Alzheimer’s disease (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lerner, Alan J., Arnold, Steven E., Maxfield, Erin, Koenig, Aaron, Toth, Maria E., Fortin, Brooke, Mast, Natalia, Trombetta, Bianca A., Denker, John, Pieper, Andrew A., Tatsuoka, Curtis, Raghupathy, Sangeetha, Pikuleva, Irina A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797897/ https://www.ncbi.nlm.nih.gov/pubmed/36581878 http://dx.doi.org/10.1186/s13195-022-01151-z

Ejemplares similares

CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020)

In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds
por: Mast, Natalia, et al.
Publicado: (2019)

The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
por: El-Darzi, Nicole, et al.
Publicado: (2023)

Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1)
por: Mast, Natalia, et al.
Publicado: (2017)

Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes
por: Petrov, Alexey M, et al.
Publicado: (2020)

Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz
por: Mast, Natalia, et al.
Publicado: (2022)

Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux
por: Mast, Natalia, et al.
Publicado: (2021)

Characterizations of Hamster Retina as a Model for Studies of Retinal Cholesterol Homeostasis
por: El-Darzi, Nicole, et al.
Publicado: (2021)

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications
por: Pikuleva, Irina A., et al.
Publicado: (2021)

Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer’s Disease
por: El-Darzi, Nicole, et al.
Publicado: (2022)

Quantitative characterizations of the cholesterol-related pathways in the retina and brain of hamsters
por: Mast, Natalia, et al.
Publicado: (2023)

N,N-Dimethyl-3β-hydroxycholenamide Reduces Retinal Cholesterol via Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its Liver X Receptor Transcriptional Activity
por: El-Darzi, Nicole, et al.
Publicado: (2018)

Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1
por: White, Mark Andrew, et al.
Publicado: (2008)

The Interplay between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina
por: Petrov, Alexey M., et al.
Publicado: (2019)

CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease
por: Boussicault, Lydie, et al.
Publicado: (2016)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Is It Possible to Improve Memory Function by Upregulation of the Cholesterol 24S-Hydroxylase (CYP46A1) in the Brain?
por: Maioli, Silvia, et al.
Publicado: (2013)

Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma
por: Han, Mingzhi, et al.
Publicado: (2019)

2-Hydroxypropyl-β-cyclodextrin mitigates pathological changes in a mouse model of retinal cholesterol dyshomeostasis
por: El-Darzi, Nicole, et al.
Publicado: (2022)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Correction: Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1)
Publicado: (2018)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Effects of a Disrupted Blood-Brain Barrier on Cholesterol Homeostasis in the Brain
por: Saeed, Ahmed A., et al.
Publicado: (2014)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

24(S),25-Epoxycholesterol and cholesterol 24S-hydroxylase (CYP46A1) overexpression promote midbrain dopaminergic neurogenesis in vivo
por: Theofilopoulos, Spyridon, et al.
Publicado: (2019)

Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis
por: Ayciriex, Sophie, et al.
Publicado: (2017)

Editorial: Cholesterol and Neurodegenerative Diseases - Pressing Questions and How to Address Them
por: Betuing, Sandrine, et al.
Publicado: (2022)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

Efavirenz and neuropsychiatric effects
por: Dheda, Mukesh
Publicado: (2017)

Efavirenz, dysrhythmia and HIV
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Localization of sterols and oxysterols in mouse brain reveals distinct spatial cholesterol metabolism
por: Yutuc, Eylan, et al.
Publicado: (2020)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

NPC1 enables cholesterol mobilization during long‐term potentiation that can be restored in Niemann–Pick disease type C by CYP46A1 activation
por: Mitroi, Daniel N, et al.
Publicado: (2019)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice
por: Anderson, Kyle W., et al.
Publicado: (2015)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7kiqnlt1rlkf2gintqvbnbci2